Neuroscience and Novel Therapeutics Unit: Meet the Team
The Neuroscience and Novel Therapeutics Unit (NNT) is a group of dedicated, compassionate, and talented scientists, clinicians, trainees, and volunteers. Our expert, interdisciplinary team works together to study and develop new treatments for children with psychiatric illnesses through innovative research, clinical care, and community outreach.
Staff Spotlight
Simone Haller, PhD has received a two-year NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation for her project “Predicting longitudinal psychiatric effects of the COVID-19 pandemic in a transdiagnostic sample of youth using rest and task-based fMRI.”
Melissa A. Brotman, PhD was awarded a second NIH Bench to Bedside Award for her proposal, in collaboration with the University of Wisconsin s Dr. Ned Kalin, entitled “Cross-Species Circuit-Based Treatment: White Matter Microstructure in Anxiety.” In 2017, a study by Drs. Brotman and Kal
Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection
In a methodological tour-de-force study, a large group of researchers from the USA and the United Kingdom analyzed patient transcriptomic data in-depth and discovered a circulating microRNA (miR-2392) that is directly implicated in the severe acute respiratory syndrome coronavirus 2 (SARS
‑
2) machinery during the infection process.
Human-to-human transmission of SARS-CoV-2 triggered an ongoing pandemic of the coronavirus disease 2019 (COVID-19) with unprecedented impact on health and economic systems worldwide. However, there is still no specific treatment for patients that develop a severe form of the illness.
And while vaccines definitely provide a promising path of disease prevention, as well as substantially curbing the infection rates, there is still a dire need to develop and implement specific therapeutic agents in order to reduce the most severe consequences from infection and ensu
Published: Apr 27, 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the company has elected neuroscience researcher and educator, Susan Hockfield, Ph.D., President Emerita of MIT, to its board of directors.
John Cox, Chief Executive Officer, Board of Directors, Repertoire Immune Medicines
“Dr. Hockfield is a tremendous addition to Repertoire Immune Medicines, as a scientist, organizational leader, and public servant,” said John Cox, CEO of Repertoire. “Our company is positioned at the frontier of immune medicines based on our ability to understand the drivers of cellular immunity. The breadth and depth of Dr. Hockfield’s experiences will help guide us along the way.”
Northern Vermont University announces speakers for Commencement 2021 vermontbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vermontbiz.com Daily Mail and Mail on Sunday newspapers.
Smith was first introduced to mindfulness meditation the practice of watching your thoughts, feelings, and sensations without judgment in the second grade. “I wasn’t necessarily a troubled kid, but sometimes I had a lot of anger,” Smith recalls. “I remember being a little confused about it, like,
Why we gotta sit and be quiet? But with more consistency, I started to be able to observe myself and became more aware of what I was actually feeling, like,
You’re not angry you’re actually sad.”
In the fall of 2012, when Smith left her home in the south suburbs of Chicago for Indiana University in Bloomington, she suddenly found herself “running around every waking hour” as a science major, president of her university’s chapter of the National Association for the Advancement of Colored People (NAACP), a member of the Alpha Kappa Alpha Sorority, and an employee at the financial aid office.